Akeso Out Licenses its Ivonescimab to Summit for ~$5B
Shots: Akeso to receive $500M up front, ~$4.5B in regulatory & commercial mile...
Immunocore Entered into an Agreement with Gadeta to Develop Gamma Delta TCR ImmTAC for Solid Tumors
Shots: Gadeta will receive an up front, near-term option fee & research milest...
IPA’s Subsidiary BioStrand Entered into a Research Collaboration and License Agreement with BriaCell to Discover and Develop Anti-...
Shots: BioStrand to receive an up front of $500,000 & will be eligible to rece...
Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies
Shots: Biocytogen to receive an up front & will be eligible to receive an opti...
Regeneron Entered into a Research Collaboration with CytomX to Develop Conditional Bispecific Therapies for the Treatment of Cance...
Shots: CytomX to receive a $30M up front along with future target nomination fees,...
NextCure Entered into a Collaboration and Co-Development Agreement with LegoChem Biosciences to Develop Antibody Drug Conjugates f...
Shots: The companies collaborated to develop B7-H4 ADC by using NextCure’s B...
